CME INFORMATION
The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity.
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IASLC 2024 World Conference on Lung Cancer (WCLC 2024) is the world’s largest international conference for clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2024 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts and posters.
The IASLC 2024 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.
At the conclusion of this activity, participants will be able to:
- Synthesize cutting-edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
- Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage thoracic malignancies.
- Collaborate on multidisciplinary teams to improve patient diagnostic, therapeutic, and palliative care through an equitable, quality, and value lens.
- Engage and empower patients to become active participants in their treatment.
- Illustrate the importance of scientific advances in the epidemiology and biology of thoracic cancer that have the potential to lead to impactful outcomes for patients and the public.
- Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and broader implementation of low-dose CT screening programs worldwide.
The official language of the IASLC 2024 World Conference on Lung Cancer is English.